Cargando…
Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe multi-systemic disease characterized by debilitating fatigue that is not relieved by rest. The causes of the disease are still largely unexplained, and no causative treatment is currently available. Changes in the immune respons...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465819/ https://www.ncbi.nlm.nih.gov/pubmed/34572574 http://dx.doi.org/10.3390/biom11091359 |
_version_ | 1784572973662863360 |
---|---|
author | Lutz, Lena Rohrhofer, Johanna Zehetmayer, Sonja Stingl, Michael Untersmayr, Eva |
author_facet | Lutz, Lena Rohrhofer, Johanna Zehetmayer, Sonja Stingl, Michael Untersmayr, Eva |
author_sort | Lutz, Lena |
collection | PubMed |
description | Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe multi-systemic disease characterized by debilitating fatigue that is not relieved by rest. The causes of the disease are still largely unexplained, and no causative treatment is currently available. Changes in the immune response are considered as fundamental in the development of ME/CFS. Thus, we aimed to evaluate the immunological profile of ME/CFS patients in a retrospective data analysis. As part of the routine workup for ME/CFS patients, a differential blood count, leukocyte subtyping, and quantification of immunoglobulins and IgG subclasses, as well as a complement analysis, was performed. Out of 262 ME/CFS patients, 64.9% had a reduction or deficiency in at least one of the listed immune parameters. In contrast, 26.3% showed signs of immune activation or inflammation. A total of 17.6% of the ME/CFS patients had an unclassified antibody deficiency, with IgG3 and IgG4 subclass deficiencies as the most common phenotypes. Reduced MBL (mannose-binding lectin) levels were found in 32% of ME/CFS patients, and MBL deficiency in 7%. In summary, the present results confirmed the relevance of immune dysfunction in ME/CFS patients underlining the involvement of a dysfunctional immune response in the disease. Thus, immune parameters are relevant disease biomarkers, which might lead to targeted therapeutic approaches in the future. |
format | Online Article Text |
id | pubmed-8465819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84658192021-09-27 Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Lutz, Lena Rohrhofer, Johanna Zehetmayer, Sonja Stingl, Michael Untersmayr, Eva Biomolecules Article Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe multi-systemic disease characterized by debilitating fatigue that is not relieved by rest. The causes of the disease are still largely unexplained, and no causative treatment is currently available. Changes in the immune response are considered as fundamental in the development of ME/CFS. Thus, we aimed to evaluate the immunological profile of ME/CFS patients in a retrospective data analysis. As part of the routine workup for ME/CFS patients, a differential blood count, leukocyte subtyping, and quantification of immunoglobulins and IgG subclasses, as well as a complement analysis, was performed. Out of 262 ME/CFS patients, 64.9% had a reduction or deficiency in at least one of the listed immune parameters. In contrast, 26.3% showed signs of immune activation or inflammation. A total of 17.6% of the ME/CFS patients had an unclassified antibody deficiency, with IgG3 and IgG4 subclass deficiencies as the most common phenotypes. Reduced MBL (mannose-binding lectin) levels were found in 32% of ME/CFS patients, and MBL deficiency in 7%. In summary, the present results confirmed the relevance of immune dysfunction in ME/CFS patients underlining the involvement of a dysfunctional immune response in the disease. Thus, immune parameters are relevant disease biomarkers, which might lead to targeted therapeutic approaches in the future. MDPI 2021-09-14 /pmc/articles/PMC8465819/ /pubmed/34572574 http://dx.doi.org/10.3390/biom11091359 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lutz, Lena Rohrhofer, Johanna Zehetmayer, Sonja Stingl, Michael Untersmayr, Eva Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
title | Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
title_full | Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
title_fullStr | Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
title_full_unstemmed | Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
title_short | Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
title_sort | evaluation of immune dysregulation in an austrian patient cohort suffering from myalgic encephalomyelitis/chronic fatigue syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465819/ https://www.ncbi.nlm.nih.gov/pubmed/34572574 http://dx.doi.org/10.3390/biom11091359 |
work_keys_str_mv | AT lutzlena evaluationofimmunedysregulationinanaustrianpatientcohortsufferingfrommyalgicencephalomyelitischronicfatiguesyndrome AT rohrhoferjohanna evaluationofimmunedysregulationinanaustrianpatientcohortsufferingfrommyalgicencephalomyelitischronicfatiguesyndrome AT zehetmayersonja evaluationofimmunedysregulationinanaustrianpatientcohortsufferingfrommyalgicencephalomyelitischronicfatiguesyndrome AT stinglmichael evaluationofimmunedysregulationinanaustrianpatientcohortsufferingfrommyalgicencephalomyelitischronicfatiguesyndrome AT untersmayreva evaluationofimmunedysregulationinanaustrianpatientcohortsufferingfrommyalgicencephalomyelitischronicfatiguesyndrome |